Trial Outcomes & Findings for Adipocytokines in Endometrial Cancer (NCT NCT04697264)
NCT ID: NCT04697264
Last Updated: 2025-03-30
Results Overview
Correlation between circulating levels of these markers and demographic characteristics such as age, parity, smoking status, menopausal status, medication use, use of HRT or hormonal contraception, the prevalence of diabetes and hypertension, any prior significant medical history or history of cancer and family history of cancer.
Recruitment status
COMPLETED
Target enrollment
100 participants
Primary outcome timeframe
Data collected at baseline
Results posted on
2025-03-30
Participant Flow
Participant milestones
| Measure |
Study - Patients With Endometrial Cancer
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
Control - Patients Without Endometrial Cancer, With Benign Gynaecological Issues
Female patients being referred to Royal Surrey NHS foundation Trust for benign conditions (specifically not endometrial cancer) will be invited to participate as the control population.
One-time blood sample from all control patients. Endometrial sample, if available and consented, from benign patients having surgery for benign gynaecological conditions.
|
|---|---|---|
|
Overall Study
STARTED
|
50
|
50
|
|
Overall Study
COMPLETED
|
50
|
50
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Adipocytokines in Endometrial Cancer
Baseline characteristics by cohort
| Measure |
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample will be collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 3/6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue collection at the time of surgery.
|
Control - Patients Without Endometrial Cancer, With Benign Gynaecological Issues
n=50 Participants
Female patients being referred to Royal Surrey NHS foundation Trust for benign conditions (specifically not endometrial cancer) will be invited to participate as the control population.
Blood from all control patients, endometrial sample from benign patients having surgery for benign gynaecological conditions.
|
Total
n=100 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
65.7 years
n=93 Participants
|
66.1 years
n=4 Participants
|
65.9 years
n=27 Participants
|
|
Sex/Gender, Customized
All participants were female
|
50 Female participants
n=93 Participants
|
50 Female participants
n=4 Participants
|
100 Female participants
n=27 Participants
|
|
Race/Ethnicity, Customized
3 Ethnicities · Caucasian
|
43 Participants
n=93 Participants
|
48 Participants
n=4 Participants
|
91 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
3 Ethnicities · Asian
|
6 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
7 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
3 Ethnicities · Afro-caribbean
|
1 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=27 Participants
|
|
Region of Enrollment
United Kingdom
|
50 participants
n=93 Participants
|
50 participants
n=4 Participants
|
100 participants
n=27 Participants
|
|
Basal Metabolic Index (BMI)
|
32.1 kg/m2
n=93 Participants
|
26.6 kg/m2
n=4 Participants
|
29.35 kg/m2
n=27 Participants
|
PRIMARY outcome
Timeframe: Data collected at baselinePopulation: HRT usage counted among menopausal women only.
Correlation between circulating levels of these markers and demographic characteristics such as age, parity, smoking status, menopausal status, medication use, use of HRT or hormonal contraception, the prevalence of diabetes and hypertension, any prior significant medical history or history of cancer and family history of cancer.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=50 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Menopause · Yes
|
42 Participants
|
39 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Menopause · No
|
8 Participants
|
11 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Smoking · Yes
|
17 Participants
|
15 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Smoking · No
|
33 Participants
|
35 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Hormonal contraception · Yes
|
32 Participants
|
30 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Hormonal contraception · No
|
18 Participants
|
20 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
HRT among menopausal women · Yes
|
20 Participants
|
10 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
HRT among menopausal women · No
|
22 Participants
|
29 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Diabetes · Yes
|
3 Participants
|
13 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Diabetes · No
|
47 Participants
|
37 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Hypertension · Yes
|
20 Participants
|
22 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Hypertension · No
|
30 Participants
|
28 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Past history of cancer · Yes
|
14 Participants
|
6 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Past history of cancer · No
|
36 Participants
|
44 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Family history of cancer · Yes
|
28 Participants
|
22 Participants
|
|
Correlation Between Circulating Levels of These Markers and Demographic Characteristics.
Family history of cancer · No
|
22 Participants
|
28 Participants
|
PRIMARY outcome
Timeframe: Data collected at baseline (day 0)Population: Study population - patients with endometrial cancer
Data on endometrial cancer histological characteristics, including grade, stage, histology, LVSI, MELF and MSI were collected from histology reports. Endometrial cancer grade is based on glandular organisation: Grade 1 (\<5% non-glandular), Grade 2 (6-50%), and Grade 3 (\>50% non-glandular). Staging reflects cancer spread, from localised to distant involvement. Type 1 (70-80%) is estrogen-related cancer usually endometrioid histology, while Type 2 (10-20%) arises from atrophic endometrium, of non-endometrioid histology. A lower grade and stage and type 1 histology is associated with better prognosis. LVSI, cancer in lymphatic/vascular spaces of the myometrium, is an independent risk factor for recurrence. MELF (microcystic, elongated, fragmented myometrial invasion) correlates with larger tumours, deeper invasion, and LVSI. MSI indicates DNA mismatch repair defects and is linked to advanced histological features, such as deep invasion and high-grade endometrial cancers.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
Grade 1
|
—
|
23 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
Grade 2
|
—
|
13 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
Grade 3
|
—
|
14 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
Stage Ia+Ib
|
—
|
41 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
Stage II+III
|
—
|
9 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
Type1 histology
|
—
|
36 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
Type 2 histology
|
—
|
14 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
LVSI present
|
—
|
15 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
LVSI absent
|
—
|
35 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
MELF present
|
—
|
6 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
MELF absent
|
—
|
29 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
MSI present
|
—
|
10 Participants
|
|
Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.
MSI absent
|
—
|
32 Participants
|
PRIMARY outcome
Timeframe: The levels of the markers between the two groups of patients were compared at baseline (day 0) and presented here.Population: Only baseline (D0/prior to surgery) levels of the markers have been listed below for comparison of baseline levels in cancer and control populations
Plasma levels of adiponectin will be measured by ELISA in both the study and the control populations, and the results compared using linear regression tests.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=50 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
The Difference in Circulating Plasma Levels of Adiponectin Between Study and Control Patients
|
11 μg/mL
Interval 3.1 to 29.6
|
5.9 μg/mL
Interval 0.8 to 27.2
|
PRIMARY outcome
Timeframe: The levels of the markers between the two groups of patients were compared at baseline (day 0) and presented here.Population: Only baseline (D0/prior to surgery) levels of the markers have been listed below for comparison of baseline levels in cancer and control populations
Plasma levels of leptin, IGF1 and IGF2 will be measured by ELISA in both the study and the control populations, and the results compared using linear regression tests.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=50 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
The Difference in Circulating Plasma Levels of Leptin, IGF1 and IGF2 Between Study and Control Patients.
Leptin
|
41.9 ng/mL
Interval 8.9 to 135.6
|
61.2 ng/mL
Interval 14.2 to 222.7
|
|
The Difference in Circulating Plasma Levels of Leptin, IGF1 and IGF2 Between Study and Control Patients.
IGF1
|
7.8 ng/mL
Interval 0.9 to 26.0
|
5.8 ng/mL
Interval 0.0008 to 19.8
|
|
The Difference in Circulating Plasma Levels of Leptin, IGF1 and IGF2 Between Study and Control Patients.
IGF2
|
19.3 ng/mL
Interval 4.2 to 54.7
|
17.3 ng/mL
Interval 2.2 to 51.2
|
PRIMARY outcome
Timeframe: The levels of the markers between the two groups of patients were compared at baseline (day 0) and presented here.Population: Only baseline (D0/prior to surgery) levels of the markers have been listed below for comparison of baseline levels in cancer and control populations
Plasma levels of IL6 and TNFα will be measured by ELISA in both the study and the control populations, and the results compared using linear regression tests.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=50 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
The Difference in Circulating Plasma Levels of IL6 and TNFα Between Study and Control Patients.
IL6
|
19.3 pg/mL
Interval 4.2 to 54.7
|
17.3 pg/mL
Interval 2.2 to 51.2
|
|
The Difference in Circulating Plasma Levels of IL6 and TNFα Between Study and Control Patients.
TNF
|
418.8 pg/mL
Interval 0.0 to 5182.0
|
118.8 pg/mL
Interval 0.0 to 3504.0
|
PRIMARY outcome
Timeframe: Levels of the markers were compared with BMI of the study patients at baseline i.e. Day 0Correlation between the markers and patients' obesity status using WHO BMI subgroups.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Correlation Between the Markers and Study Patients' Obesity Status
|
—
|
32.1 kg/m2
Interval 18.6 to 54.0
|
PRIMARY outcome
Timeframe: BMI was measured at baseline only for the control population.Correlation between the markers and patients' obesity status using WHO BMI subgroups.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Correlation Between the Markers and Control Patients' Obesity Status
|
—
|
26.6 kg/m2
Interval 18.5 to 43.0
|
SECONDARY outcome
Timeframe: 6 monthsLevels of biomarkers were assessed at baseline, at day 1, and at 6 months post-surgery in endometrial cancer patients (study population). To assess the effect of treatment i.e. surgery +/- adjuvant treatment on the levels of the biomarkers, associations were sought between the levels of biomarkers before surgery (day 0) and 6 months post-surgery and the results have been presented here.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=50 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Changes in Adiponectin Levels Before (Day 0) and After Surgery in the Study Population (at 6 Months).
|
2.26 μg/mL
Standard Error 0.085
|
2.59 μg/mL
Standard Error 0.086
|
SECONDARY outcome
Timeframe: 6 monthsLevels of biomarkers were assessed at baseline, at day 1, and at 6 months post-surgery in endometrial cancer patients (study population). To assess the effect of treatment i.e. surgery +/- adjuvant treatment on the levels of the biomarkers, associations were sought between the levels of biomarkers before surgery (day 0) and 6 months post-surgery and the results have been presented here.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=50 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Changes in Leptin, IGF1 and IGF2 Levels Before (Day 0) and After Surgery in the Study Population (at 6 Months).
Leptin
|
5.51 ng/mL
Standard Error 0.115
|
5.42 ng/mL
Standard Error 0.117
|
|
Changes in Leptin, IGF1 and IGF2 Levels Before (Day 0) and After Surgery in the Study Population (at 6 Months).
IGF1
|
2.94 ng/mL
Standard Error 0.112
|
2.59 ng/mL
Standard Error 0.113
|
|
Changes in Leptin, IGF1 and IGF2 Levels Before (Day 0) and After Surgery in the Study Population (at 6 Months).
IGF2
|
4.85 ng/mL
Standard Error 0.132
|
3.93 ng/mL
Standard Error 0.133
|
SECONDARY outcome
Timeframe: 6 monthsLevels of biomarkers were assessed at baseline, at day 1, and at 6 months post-surgery in endometrial cancer patients (study population). To assess the effect of treatment i.e. surgery +/- adjuvant treatment on the levels of the biomarkers, associations were sought between the levels of biomarkers before surgery (day 0) and 6 months post-surgery and the results have been presented here.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=50 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=50 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Changes in IL6 and TNFα Levels Before (Day 0) and After Surgery in the Study Population (at 6 Months).
TNF
|
3.62 pg/mL
Standard Error 0.409
|
3.70 pg/mL
Standard Error 0.413
|
|
Changes in IL6 and TNFα Levels Before (Day 0) and After Surgery in the Study Population (at 6 Months).
IL6
|
3.01 pg/mL
Standard Error 0.415
|
2.84 pg/mL
Standard Error 0.419
|
SECONDARY outcome
Timeframe: The expression of these markers were investigated in the two tissue samples at baseline only (day 0).Expression of adiponectin, leptin, and their receptors were studied in endometrial cancer tissue and fat tissue using qRT-PCR. Fresh endometrial tissue was collected from 39 endometrial cancer and 5 control patients. Fresh adipose tissue was collected from these 39 endometrial cancer patients. Normal endometrium was used as a reference (calibrator sample) and the expressions of the biomarkers were calculated as fold changes compared to the expression in the calibrator sample using the delta-delta Ct formula. A higher fold change indicates greater expression of the marker in the study sample compared to the benign calibrator sample. This allowed for a standardised comparison of biomarker expression across different tissues, such as cancerous and adipose tissues.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=39 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=39 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Adipose Tissue
Adiponectin / AdipoQ
|
10165.2 fold change
Interval 47.5 to 50360.3
|
116.6 fold change
Interval 0.0 to 2846.6
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Adipose Tissue
AdipoQ receptor / ADIPOR1
|
0.839 fold change
Interval 0.0 to 6.34
|
3.15 fold change
Interval 0.0 to 54.4
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Adipose Tissue
AdipoQ receptor/ ADIPOR2
|
1.741 fold change
Interval 0.0 to 4.3
|
1.689 fold change
Interval 0.0 to 20.8
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Adipose Tissue
Leptin / Ob
|
3765.1 fold change
Interval 4.3 to 38967.9
|
263.7 fold change
Interval 0.0 to 4560.6
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Adipose Tissue
Leptin receptor/ ObR
|
1.432 fold change
Interval 0.0 to 6.43
|
0.328 fold change
Interval 0.0 to 4.4
|
SECONDARY outcome
Timeframe: The expression of these markers were investigated in the two tissue samples at baseline only (day 0).The expression of adiponectin and leptin and their receptors were studied in endometrial cancer tissue and lymph node tissue using qRT-PCR. 12 FFPE lymph nodal tissue blocks were collected from patients with lymph node dissection. Fresh endometrial tissue was collected from 39 endometrial cancer and 5 control patients, however, the data for the 12 patients with lymph node dissection is presented here. Normal endometrium was used as a reference (calibrator sample) and the expressions of the biomarkers were calculated as fold changes compared to the expression in the calibrator sample using the delta-delta Ct formula. A higher fold change indicates greater expression of the marker in the study sample compared to the benign calibrator sample. This allowed for a standardised comparison of biomarker expression across different tissues, such as cancerous and lymph nodal tissue.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
n=12 Participants
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=12 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
Adiponectin / AdipoQ
|
653.235 fold change
Interval 39.95 to 4803.93
|
19.18 fold change
Interval 0.0 to 102.2
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
ADIPOR1
|
1.37 fold change
Interval 0.08 to 13.59
|
0.69 fold change
Interval 0.0 to 2.7
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
ADIPOR2
|
10.10 fold change
Interval 0.61 to 94.03
|
1.35 fold change
Interval 0.0 to 4.44
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
Leptin / Ob
|
11448.21 fold change
Interval 174.25 to 82094.62
|
97.57 fold change
Interval 0.0 to 935.8
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
Leptin receptor/ ObR
|
3.47 fold change
Interval 0.28 to 34.3
|
0.15 fold change
Interval 0.0 to 0.67
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
IGF1
|
4.5125 fold change
Interval 0.04 to 51.63
|
1.42 fold change
Interval 0.0 to 9.2
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
IGF1R
|
7.49 fold change
Interval 0.15 to 73.26
|
1.15 fold change
Interval 0.13 to 3.74
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
IGF2
|
5.33 fold change
Interval 0.06 to 61.82
|
8.20 fold change
Interval 0.0 to 37.0
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
IGF2R
|
0.73 fold change
Interval 0.31 to 1.29
|
1.67 fold change
Interval 0.0 to 3.15
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
IL6
|
4100.21 fold change
Interval 3.29 to 32881.76
|
461.5 fold change
Interval 0.3 to 4269.9
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
IL6R
|
1238.38 fold change
Interval 3.2 to 14263.1
|
4.56 fold change
Interval 0.26 to 13.25
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
TNF
|
23.46 fold change
Interval 2.57 to 103.97
|
12.25 fold change
Interval 0.0 to 85.0
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
TNFR1A
|
144.9691667 fold change
Interval 0.3 to 1332.57
|
4.80 fold change
Interval 0.37 to 10.36
|
|
Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Lymph Nodal Tissue
TNFR1B
|
11.5525 fold change
Interval 2.73 to 59.1
|
6.11 fold change
Interval 0.58 to 41.83
|
SECONDARY outcome
Timeframe: At baseline, one time point measurement, Day 0Correlation between circulating adiponectin levels (measured by ELISA) and their expression in endometrial tissue (measured by PCR). This was done for the 39 patients from whom we received the tissue sample.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=39 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Correlation Between Circulating Adiponectin Levels and Their Expression in Endometrial Tissue.
|
—
|
5.76 μg/ml
Interval 0.78 to 21.02
|
SECONDARY outcome
Timeframe: At baseline, one time point measurement, Day 0Correlation between circulating leptin, IGF1 and IGF2 levels (measured by ELISA) and their expression in endometrial tissue (measured by PCR). This was done for the 39 patients from whom we received the tissue sample.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=39 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Correlation Between Circulating Leptin, IGF1 and IGF2 Levels and Their Expression in Endometrial Tissue.
Leptin
|
—
|
57.99 ng/mL
Interval 14.23 to 138.68
|
|
Correlation Between Circulating Leptin, IGF1 and IGF2 Levels and Their Expression in Endometrial Tissue.
IGF1
|
—
|
5.73 ng/mL
Interval 0.008 to 19.81
|
|
Correlation Between Circulating Leptin, IGF1 and IGF2 Levels and Their Expression in Endometrial Tissue.
IGF2
|
—
|
16.35 ng/mL
Interval 2.19 to 51.19
|
SECONDARY outcome
Timeframe: At baseline, one time point measurement, Day 0Correlation between circulating IL6 and TNF levels (measured by ELISA) and their expression in endometrial tissue (measured by PCR). This was done for the 39 patients from whom we received the tissue sample.
Outcome measures
| Measure |
Study Population - 6 Months Post Surgery
Study population was followed up 6 months post surgery and levels of the markers were analysed in their blood.
|
Study - Patients With Endometrial Cancer
n=39 Participants
Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
Blood sample were collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 6 months post-surgery follow-up in clinic.
Endometrial and adipose tissue samples collected at the time of surgery.
|
|---|---|---|
|
Correlation Between Circulating IL6 and TNF Levels and Their Expression in Endometrial Tissue.
IL6
|
—
|
31.71 pg/mL
Interval 0.0 to 288.39
|
|
Correlation Between Circulating IL6 and TNF Levels and Their Expression in Endometrial Tissue.
TNF
|
—
|
57.13 pg/mL
Interval 0.0 to 812.58
|
Adverse Events
Study - Patients With Endometrial Cancer
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Control - Patients Without Endometrial Cancer, With Benign Gynaecological Issues
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place